Blog
RSS FeedPosted by Michael Wonder on 14 Nov 2024
Teclistamab for the treatment of patients with relapsed and refractory multiple myeloma after three or more treatments (final guidance)
13 November 2024 - NICE has published final evidence-based recommendations on the use of teclistamab (Tecvayli) for the treatment of ...
Posted by Michael Wonder on 13 Nov 2024
Sanofi wins appeal in spat with NICE over Sarclisa
13 November 2024 - Sanofi has taken a small step towards potentially overturning a recent rejection by NICE for NHS ...
Posted by Michael Wonder on 13 Nov 2024
Alectinib hydrochloride for the adjuvant treatment of patients with ALK positive non-small-cell lung cancer
13 November 2024 - NICE has published final evidence-based recommendations on the use of alectinib hydrochloride for the adjuvant treatment ...
Posted by Michael Wonder on 11 Nov 2024
MHRA grants marketing authorisation for Balversa (erdafitinib) as monotherapy for the treatment of adults with unresectable or metastatic urothelial carcinoma (UC) harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting
6 November 2024 - Erdafitinib is the first and only bladder cancer therapy that targets FGFR3 alterations and has been ...
Posted by Michael Wonder on 06 Nov 2024
Avapritinib for the treatment of patients with advanced systemic mastocytosis
6 November 2024 - NICE has published evidence-based recommendations on the use of avapritinib (Ayvakyt) for the treatment of adults ...
Posted by Michael Wonder on 06 Nov 2024
Fenfluramine hydrochloride for the treatment of patients 2 years of age and older with seizures associated with Lennox–Gastaut syndrome
5 November 2024 - Following an appeal, NICE has published further draft guidance on the use of using fenfluramine hydrochloride ...
Posted by Michael Wonder on 31 Oct 2024
Sugemalimab approved to treat adult patients with non-small cell lung cancer
30 October 2024 - The MHRA has today approved sugemalimab (Eqjubi) to treat adult patients with non-small cell lung cancer. ...
Posted by Michael Wonder on 31 Oct 2024
Leniolisib phosphate for the treatment of patients 12 years of age and older with activated phosphoinositide 3-kinase delta syndrome
31 October 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 30 Oct 2024
Osimertinib mesylate in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with advanced EGFR mutation positive non-small-cell lung cancer
30 October 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 30 Oct 2024
Eplontersen for the treatment of patients with hereditary transthyretin related amyloidosis
29 October 2024 - NICE has published final drat guidance on the use of eplontersen for the treatment of patients ...
Posted by Michael Wonder on 29 Oct 2024
People with a rare form of blood cancer are set to benefit after NICE recommends new targeted therapy
29 October 2024 - Hundreds of people with a rare form of blood cancer could be set to benefit after NICE ...
Posted by Michael Wonder on 24 Oct 2024
Driving down the cost of biologics: lessons from a nationalised health care system
18 October 2024 - Few treatments have revolutionised care for people with chronic inflammatory disorders more than biologic and small molecule ...
Posted by Michael Wonder on 24 Oct 2024
Quizartinib dihydrochloride for the induction, consolidation and maintenance treatment of adults with newly diagnosed FLT3-ITD positive acute myeloid leukaemia
23 October 2024 - NICE has published final evidence-based recommendations on the use of quizartinib dihydrochloride (Vanflyta) for the induction, ...
Posted by Michael Wonder on 23 Oct 2024
Lilly's Kisunla (donanemab-azbt) receives marketing authorisation in Great Britain for the treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease in adult patients who are apolipoprotein E Ε4 heterozygotes or non-carriers
23 October 2024 - Donanemab was first approved in the United States in July 2024 and then approved in Japan ...
Posted by Michael Wonder on 23 Oct 2024
New Alzheimer’s treatment donanemab does not currently demonstrate value for the NHS says NICE
23 October 2024 - More evidence is needed on the clinical and cost effectiveness of donanemab, a new treatment for mild ...